What Is GHRP-2 Studied For? Research Areas, Per the Literature

GHRP-2, also called pralmorelin, KP-102 and GPA-748, is a synthetic hexapeptide classed as a growth hormone secretagogue. A drug profile of pralmorelin described it as a growth hormone-releasing peptide developed for diagnostic and therapeutic investigation of growth hormone secretion (PMID 15230633). Structure-activity work on peptidic growth hormone secretagogues placed GHRP-2 within a family of short synthetic peptides that act at the growth hormone secretagogue receptor rather than at the growth hormone-releasing hormone receptor (PMID 26811125).

GHRP-2 is not approved by the FDA as a medicine for any condition. This page is not guidance. This page is for educational purposes only and is not medical advice; consult a licensed physician about any health question or any medication decision.

The question "what is GHRP-2 used for" is answered here only as what researchers have studied it for. Each area below names the study type (in vitro, animal or human), the population or model, and carries its PubMed citation in the same passage.

Research Area 1: Growth Hormone Stimulation Testing in Humans

The best developed human application in the published record is diagnostic rather than therapeutic. The pralmorelin drug profile described GHRP-2 as investigated for assessing growth hormone secretory capacity, with development centred on its ability to provoke a measurable growth hormone response (PMID 15230633).

Obesity and the GHRP-2 stimulated response

A human clinical study in patients with obesity undergoing laparoscopic sleeve gastrectomy reported that low GHRP-2-stimulated growth hormone levels present before surgery resolved after the procedure, which the authors interpreted as the blunted growth hormone axis in obesity being reversible with weight loss rather than reflecting fixed pituitary failure (PMID 28623445). In that work GHRP-2 served as the provocative test agent, not as a treatment.

Comparison with other provocative agents

A human study in subjects with growth hormone-releasing hormone resistance syndrome examined growth hormone responses to hypoglycemia and to clonidine, illustrating how different stimuli probe different points of the somatotropic axis in a genetically defined population (PMID 17114911). That literature is the context in which secretagogue-based testing has been evaluated, because an agent acting at the ghrelin receptor interrogates a different pathway than growth hormone-releasing hormone itself (PMID 26811125).

Research Area 2: Appetite and Food Intake

Human data

A controlled study in healthy men reported that GHRP-2, like ghrelin, increased food intake, positioning the peptide as an appetite-stimulating ligand at the ghrelin receptor in humans (PMID 15699539). This is one of the few human studies in which GHRP-2 was given to test a physiological outcome other than growth hormone release, and the population studied was healthy adult men rather than patients with an eating or wasting disorder (PMID 15699539).

Animal data pointing the other way

Species differences matter. An animal study in neonatal chicks reported that chicken ghrelin and GHRP-2 inhibited food intake, the opposite direction from the human finding (PMID 12393062). Read together, the healthy-men study and the chick study show that appetite effects of ghrelin receptor agonists are not uniform across species (PMID 15699539, PMID 12393062).

Research Area 3: Cachexia and Wasting

Because ghrelin receptor agonism increases food intake in healthy men (PMID 15699539), the class has been discussed in the cachexia literature. A review of pharmacotherapy in cachexia surveyed endocrine abnormalities and steroid pharmacotherapy in wasting syndromes and framed hormonal approaches as part of a broader and still unsettled treatment landscape (PMID 35758863). A review of ghrelin receptor ligands reaching clinical trials traced how peptides and peptidomimetics, agonists and antagonists alike, have been advanced toward clinical evaluation for indications linked to appetite and metabolism (PMID 26551992).

What the verified literature does not contain is a completed GHRP-2 outcome trial in cancer cachexia or similar wasting populations demonstrating preserved lean mass or survival. The reviews describe the class and its clinical development path (PMID 26551992, PMID 35758863); they are not evidence that GHRP-2 itself changes those endpoints.

Research Area 4: Body Composition and Hypogonadal Men

A review of approaches beyond the androgen receptor examined the role of growth hormone secretagogues in the management of body composition in hypogonadal males, discussing the class as an area of interest alongside conventional androgen-focused strategies (PMID 32257855). This is narrative review material rather than a randomised body composition trial of GHRP-2, and the review's framing is a discussion of mechanism and clinical interest (PMID 32257855).

Stated plainly: for the popular search framing of GHRP-2 as a body composition agent, the verified evidence base is review-level and mechanistic (PMID 32257855, PMID 26811125), not controlled human outcome data.

Summary Table of Research Areas

Where the Evidence Is Weak or Absent

Several uses commonly attached to GHRP-2 in general discussion are not supported by the verified literature set and are listed here as gaps rather than as findings.

• Sleep quality. No study in the verified set measured sleep outcomes with GHRP-2. The closest material is class-level review discussion of ghrelin receptor ligands in clinical development (PMID 26551992).
• Injury recovery or tendon healing. Absent from the verified set; the structure-activity and detection literature addresses chemistry and analysis, not tissue repair (PMID 26811125).
• Fat loss as a measured endpoint. Not demonstrated in a controlled trial within this set; body composition appears only in review discussion of hypogonadal males (PMID 32257855).
• Anti-ageing or longevity. No study in the verified set examined lifespan or ageing endpoints (PMID 15230633).

Safety and Tolerability: What Studies Report

The verified set is weighted toward diagnostic, mechanistic and analytical work, so systematic adverse event tabulation is limited. The pralmorelin drug profile covered the compound's development as a growth hormone-releasing peptide, which is the appropriate source for its regulatory and development status rather than for long-term safety conclusions (PMID 15230633). The review of ghrelin receptor ligands reaching clinical trials described the progression of agonists and antagonists through clinical evaluation, which implies ongoing tolerability assessment at the class level rather than a settled safety profile for GHRP-2 specifically (PMID 26551992).

A distinct and documented risk sits outside pharmacology. Analytical investigation of black market follistatin 344 reported that products sold outside regulated channels can differ from their labelling, a finding that bears on any unregulated peptide preparation (PMID 31758732).

How to Read This Literature

1. Separate diagnostic from therapeutic. Most robust human GHRP-2 data describe its use as a provocative test agent, as in the sleeve gastrectomy study where stimulated growth hormone levels normalised after surgery (PMID 28623445).
2. Check the species. Appetite rose in healthy men (PMID 15699539) and fell in neonatal chicks (PMID 12393062).
3. Distinguish review from trial. Cachexia and body composition material in this set is review-level (PMID 35758863, PMID 32257855).
4. Note the analytical bias. A large portion of published GHRP-2 work exists to support detection, not clinical use (PMID 25469748).

Closing Note

GHRP-2 is not approved by the FDA as a medicine for any condition. This page is not guidance. The material above summarises what researchers have reported in the published record and nothing more. This page is for educational purposes only and is not medical advice; consult a licensed physician about any health question. For background on the molecule itself, see the related overview at /learn/ghrp-2/.

References

• Pralmorelin: GHRP 2, GPA 748, growth hormone-releasing peptide 2, KP-102 D, KP-102 LN, KP-102D, KP-102LN (Drugs in R&D, 2004)
• Laparoscopic Sleeve Gastrectomy Resolves Low GHRP-2-Stimulated Growth Hormone Levels in Obese Patients (Obesity Surgery, 2017)
• Growth hormone releasing peptide-2 (GHRP-2), like ghrelin, increases food intake in healthy men (The Journal of Clinical Endocrinology and Metabolism, 2005)
• Chicken ghrelin and growth hormone-releasing peptide-2 inhibit food intake of neonatal chicks (European Journal of Pharmacology, 2002)
• Structure-activity relationship for peptidic growth hormone secretagogues (Drug Testing and Analysis, 2017)
• Ghrelin Receptor Ligands Reaching Clinical Trials: From Peptides to Peptidomimetics; from Agonists to Antagonists (Hormone and Metabolic Research, 2016)
• Pharmacotherapy in Cachexia: A Review of Endocrine Abnormalities and Steroid Pharmacotherapy (Journal of Pain & Palliative Care Pharmacotherapy, 2022)
• Beyond the androgen receptor: the role of growth hormone secretagogues in the modern management of body composition in hypogonadal males (Translational Andrology and Urology, 2020)
• Growth hormone secretagogues: out of competition (Analytical and Bioanalytical Chemistry, 2012)
• In vitro models for metabolic studies of small peptide hormones in sport drug testing (Journal of Peptide Science, 2015)
• GH response to hypoglycemia and clonidine in the GH-releasing hormone resistance syndrome (Journal of Endocrinological Investigation, 2006)
• Detection of black market follistatin 344 (Drug Testing and Analysis, 2019)